Table II. Serum 25-hydroxyvitamin D status: ALL survivors requiring chemotherapy compared with those requiring hematopoietic stem cell transplant and ALL survivors compared to child and adolescent healthy population from NHANES.
| Non-HCT n= 52 |
HCT n= 26 |
p-value | NHANES1 | ALL Survivors n= 78 |
CI | p-value | |
|---|---|---|---|---|---|---|---|
| Serum 25 hydroxy-vitamin D(ng/ ml)2 | 26.0 (21.0-33.2) | 25.5 (21.0-33.2) | 0.953 | ||||
| Deficient (<15 ng/mL) | 11.5% | 11.5% | 0.994 | 9% | 11.5% | 4.5% to 18.5% | 0.314 |
| Insufficient (15-29 ng/mL) | 51.9% | 53.8% | 61% | 52.6% | 41.6% to 63.5% | ||
| Normal (≥ 30 ng/mL) | 36.5% | 34.6% | 30% | 35.9% | 25.4% to 46.4% |
1
Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and Associations of 25-Hydroxyvitamin D Deficiency in US Children: NHANES 2001-2004. Pediatrics 2009;
2
presented as the median and (25th – 75th percentile);
3
Wilcoxon rank sum test;
4
Chi-squared test